Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7-Targeted CAR-T Cells in r/r CD7-Positive Hematological Malignancies
NCT07345780Not yet recruiting
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial in CD7-positive hematological malignancies, T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoblastic lymphoma (T-LBL) and 1 more. Primary endpoint: Overall survival at 24 months. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
CD7-positive hematological malignanciesT-cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoblastic lymphoma (T-LBL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07345780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07345780.